Hisky Medical
Hisky enhances Metabolic Health Assessments.
Hisky, founded at Tsinghua University, is dedicated to advancing innovative diagnostic and treatment technologies to improve global health. The company’s mission is to “Popularize High-end Technology, Protect Public Health,” reflecting its commitment to making advanced healthcare solutions accessible to all. Hisky’s iLivTouch® elastography platform —a non-invasive liver diagnostic tool powered by Vibration-Controlled Transient Elastography (TE) is an advanced imaging method that measures liver stiffness early. The iLivTouch® system provides fast, comprehensive, and accurate results, supporting the assessment of liver fibrosis and steatosis, and is particularly vital for managing chronic liver diseases, including MASH and MASLD.
In one study, iLivTouch® has enabled earlier detection of liver fibrosis in over 500,000 patients, resulting in timely interventions and improved health outcomes. This approach has proven essential for both chronic liver disease management and routine liver health screenings. The effectiveness and reliability of TE have led to its recommendation in liver disease guidelines issued by the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL), and the World Health Organization (WHO).
Hisky invests heavily in research and development. The company has applied for and secured more than 600 patents worldwide, achieving international standards in cutting-edge optical systems, acoustics, and intelligent imaging. Hisky’s commitment to quality and safety is further demonstrated by its certifications from global regulatory bodies, including the FDA, CE, PMDA, TGA, KFDA, and others. Today, Hisky’s products are available in over 60 countries and regions, including the United States, and have helped tens of millions of patients worldwide with thousands of iLivTouch® systems installed worldwide.
